Crossmark

Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control

Crossref DOI link: https://doi.org/10.1007/s00592-022-01937-5

Published Online: 2022-07-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lepore, Giuseppe https://orcid.org/0000-0002-2990-8181
Rossini, Alessandro

Bellante, Rosalia

Corsi, Anna

Scaranna, Cristiana

Dodesini, Alessandro Roberto

Trevisan, Roberto
License Information

Text and Data Mining valid from 2022-07-20

Version of Record valid from 2022-07-20
More Information

Article History

Received: 29 May 2022

Accepted: 29 June 2022

First Online: 20 July 2022

Declarations

:

: The authors declare no conflict of interest in connection with submitted material.

: Written informed consent to use the clinical and biochemical data was obtained from all participants.

: All procedures performed in this study involving human participants were in accordance with the Ethical Standard of their institutional and national Research Committee and with the 1964 Helsinky Declaration and its later amendments or comparable ethical standard.

Document is current

Any future updates will be listed below